Raphael Pharmaceutical (RAPH) Share-based Compensation (2022 - 2025)
Raphael Pharmaceutical (RAPH) reported Share-based Compensation of $1000.0 for Q4 2025, down 99.65% on a YoY basis from $289000.0 in Q4 2024, and down 97.44% sequentially from $39000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Share-based Compensation (2022 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 3 years of Share-based Compensation data on file, last reported at $1000.0 in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation fell 99.65% year-over-year to $1000.0; the trailing twelve-month figure through Dec 2025 stood at $245000.0 (up 64.43% YoY), and the FY2025 full-year result was $245000.0, down 30.0% from the prior year.
- Share-based Compensation slipped to $1000.0 in Q4 2025, from $39000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.2 million in Q3 2022 to a low of -$1.3 million in Q4 2022.
- A 3-year average of $76000.0 and a median of $140000.0 in 2022 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 99.65% in 2025, while the deepest fall reached 99.65% in 2025.
- Tracing RAPH's Share-based Compensation over 3 years: stood at -$1.3 million in 2022, then jumped by 121.57% to $289000.0 in 2024, then sank by 99.65% to $1000.0 in 2025.
- Business Quant data shows RAPH's Share-based Compensation at $1000.0 in Q4 2025, $39000.0 in Q3 2025, and $8000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Dec 31, 2022 | -1.34 Mn |
| Dec 31, 2022 | -1.34 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 140,000.00 |
| Jun 30, 2022 | 140,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Mar 31, 2022 | 150,000.00 |